A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
← catalyst calendarNCT06653153 · readout ≤ 985 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
1,400estimated
Sites
262
Countries
Australia, Canada, China +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-24 | actual | When the study began enrolling |
| Primary completion | Apr 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer's Disease
Interventions
- Drug: Remternetug — also filed as LY3372993
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)
measured Baseline to Time to Event up to Week 255
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed